| Date | Company | Compound | Disease | Type of agreement | Therapeutic area | Type of Information |
|---|---|---|---|---|---|---|
| 2014-05-28 | Roche (Switzerland) 20/20 HealthCare Partners (USA - MA) | collaboration |
Cancer - Oncology - CNS diseases - Infectious diseases - Inflammatory diseases - Ophthalmological diseases | Collaboration agreement | ||
| 2014-05-28 | PolyTherics (UK) Alpha Cancer Technologies (Canada) | alpha fetoprotein drug conjugate | ovarian cancer | collaboration R&D |
Cancer - Oncology | R&D agreement |
| 2014-05-28 | Bind Therapeutics (USA - MA) | chief financial officer | nomination | Cancer - Oncology | Nomination | |
| 2014-05-27 | BioInvent (Sweden) Alligator Bioscience (Sweden) | ADC-1013 | product acquisition | Cancer - Oncology | Product acquisition | |
| 2014-05-27 | BioVersys (Switzerland) University of Lille (France) GSK (UK) | tuberculosis | collaboration |
Infectious diseases | Collaboration agreement | |
| 2014-05-27 | Orient EuroPharma (Singapour) Debiopharm (Switzerland) | Pamorelin® LA (triptorelin) | locally advanced or metastatic, hormone-dependent prostate cancer. | commercialisation distribution |
Cancer - Oncology | Distribution agreement |
| 2014-05-23 | Chugai Pharmaceuticals (Japan) Roche (Switzerland) | antibody engineering technologies | licensing |
Technology - Services | Licensing agreement | |
| 2014-05-23 | Servier (France) CNRS (France) University of Montpellier 1 (France) University of Montpellier 2 (France) | inhibitors of apoptosis | myocardial infarction | R&D - collaboration | Cardiovascular diseases | Collaboration agreement |
| 2014-05-21 | Roslin Cells (UK) Pfizer (USA - NY) | retinal pigment epithelium (RPE) cells to be used in a cell therapy clinical trial | age related macular degeneration | services |
Ophtalmological diseases | Services contract |
| 2014-05-21 | Wilex (Germany) UCB (Belgium) | WX-554, WX-037 and for three preclinical antibody programmes | R&D licensing |
Cancer - Oncology | Termination of an agreement | |
| 2014-05-21 | ImaginAb (USA - CA) | establishment of a new subsidiary in Japan |
Cancer - Oncology - Autoimmune diseases - Technology - Services | Establishment of a new subsidiary in the EU | ||
| 2014-05-21 | Nuevolution (Denmark) | member of the board of directors | nomination | Technology - Services | Nomination | |
| 2014-05-20 | Cell Therapy Catapult (UK) Imperial Innovations (UK) UCL Business (UK) | gene-modified T-cell receptor therapy targeting WT1-overexpressing cells | acute myeloid leukaemia | development |
Cancer - Oncology | Development agreement |
| 2014-05-19 | Cardio3 BioSciences (Belgium) Viromed (South Korea) | C-Cathez® | ischemic cardiovascular diseases | commercialisation |
Cardiovascular diseases | Commercialisation agreement |
| 2014-05-19 | Novartis (Switzerland) Ophthotech (USA - NY) | Fovista® | licensing commercialisation |
Licensing agreement | ||
| 2014-05-15 | Eurofins Genomics (Germany) UK Shared Business Services Ltd (UK SBS) (UK) | oligonucleotides and DNA sequencing services | services |
Technology - Services | Services contract | |
| 2014-05-15 | Enigma Diagnostic (UK) National Institute for Communicable Disease Control and Prevention, China Center for Disease Control and Prevention (China) | molecular diagnostic technology for infectious disease pathogens utilising Enigma’s proprietary chemistries and the Enigma® Mini Laboratory system (“Enigma ML”) | development |
Diagnostic - Infectious diseases | Development agreement | |
| 2014-05-14 | MedImmune (USA - global biologics arm of AstraZeneca (UK) - Incyte Corporation (USA- DE) | MEDI4736 and INCB24360 | multiple solid tumours including metastatic melanoma, non-small cell lung cancer, squamous cell carcinoma of the head and neck and pancreatic cancer | clinical research |
Cancer - Oncology | Clinical research agreement |
| 2014-05-14 | Ligand Pharmaceuticals (USA - CA) Omthera Pharmaceuticals (USA - NJ), a wholly-owned subsidiary of AstraZeneca (UK) | dyslipidemia, including hypertriglyceridemia | R&D licensing |
Metabolic diseases | R&D agreement | |
| 2014-05-14 | CSL (Australia) ASLAN Pharmaceuticals (Singapore) | CSL334 (anti-IL13 receptor monoclonal antibody) | asthma | licensing |
Allergic diseases - Inflammatory diseases - Respiratory diseases | Licensing agreement |
